Pantoprazole

Pantoprazole, the active ingredient in Pantoprazole, is a proton pump inhibitor presented as a / for oral use. It treats acid‑related disorders such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and Zollinger‑Ellison syndrome in adults.

GNH USA supplies Pantoprazole as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Pantoprazole belongs to the proton pump inhibitor class and is used to manage acid‑related gastrointestinal conditions. - Gastro‑oesophageal reflux disease (GERD): reduction of reflux symptoms and healing of esophageal irritation. - Erosive esophagitis: promotes healing of erosive lesions in the esophagus. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion.

Pantoprazole may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually self‑limiting. - Nausea: occasional feeling of queasiness. - Abdominal pain: discomfort in the upper abdomen. - Flatulence: increased gas formation. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rash, swelling, difficulty breathing. - Clostridioides difficile infection: severe colitis with watery diarrhea. - Elevated liver enzymes: signs of hepatic stress. - Hypomagnesemia: low magnesium levels causing muscle cramps. - Stevens‑Johnson syndrome: severe skin and mucous membrane reaction. - Interstitial nephritis: inflammation of kidney tissue.

When prescribing Pantoprazole, clinicians should consider several safety aspects. - Renal impairment: dose adjustment may be required. - Hepatic impairment: use with caution in patients with liver disease. - Elderly patients: monitor for dehydration and electrolyte imbalance. - Concomitant warfarin therapy: monitor INR closely due to potential interaction. - Pregnancy and lactation: safety not established; weigh benefits against potential risks. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture.

Pantoprazole can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, leading to sub‑therapeutic levels. - Methotrexate: increased toxicity due to reduced renal clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring dose adjustment. - Digoxin: may raise serum concentrations, necessitating monitoring. - Diazepam: potential increase in plasma levels, watch for enhanced sedation.